Methsuximide

CHEMBL697 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
203.2 g/mol
LogP
1.2
Phase
4

An anticonvulsant medication used to control absence seizures (brief lapses of consciousness) in patients with epilepsy who have not responded to other seizure medications. It works by reducing abnormal electrical activity in the brain.

分子量

203.2400 g/mol

LogP

1.20

TPSA

37.40 Ų

リピンスキーの五則

適合

治療領域

作用機序

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1C(=O)CC(C)(c2ccccc2)C1=O

InChI

InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3

Molecular Formula

C12H13NO2

HBD / HBA

- / 2

回転可能結合数

1

重原子数

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An anticonvulsant medication used to control absence seizures (brief lapses of consciousness) in patients with epilepsy who have not responded to other seizure medications. It works by reducing abnormal electrical activity in the brain.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Methsuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL697. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6476. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.